{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000057","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.778176+00:00","generated_at":"2026-06-01T05:17:11.978274+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Akebia Therapeutics shareholders reject proposal to increase share reserve by 9.8M shares","bullets":["Three Class I directors elected: Ronald E. Frieson, Steven C. Gilman, Ph.D., Cynthia Smith.","Proposal to increase 2023 Stock Incentive Plan by 9.8M shares failed (52.8M against vs 45.2M for).","Advisory say-on-pay compensation approved narrowly (48.9M for, 47.4M against).","Ratification of Ernst & Young as independent auditor for FY 2024 approved (120.2M for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000057","json":"https://secwatch.observer/filing/0001517022-24-000057.json","markdown":"https://secwatch.observer/filing/0001517022-24-000057.md","text":"https://secwatch.observer/filing/0001517022-24-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000057/0001517022-24-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000057/akba-20241006cfo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:17:11.978274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}